Attached files
file | filename |
---|---|
10-Q - FORM 10-Q - CYPRESS BIOSCIENCE INC | a54286e10vq.htm |
EX-32 - EX-32 - CYPRESS BIOSCIENCE INC | a54286exv32.htm |
EX-31.2 - EX-31.2 - CYPRESS BIOSCIENCE INC | a54286exv31w2.htm |
EX-31.1 - EX-31.1 - CYPRESS BIOSCIENCE INC | a54286exv31w1.htm |
Exhibit 3.2
CERTIFICATE OF AMENDMENT OF
SECOND AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION OF
CYPRESS BIOSCIENCE, INC.
SECOND AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION OF
CYPRESS BIOSCIENCE, INC.
Cypress Bioscience, Inc., a corporation organized and existing under and by virtue of the
General Corporation Law of the State of Delaware, hereby certifies that:
One: The name of this corporation is Cypress Bioscience, Inc. and the date of filing
the original Certificate of Incorporation of this corporation with the Secretary of State of the
State of Delaware was October 21, 1981 under the name Immune Response Systems, Inc. The
Certificate of Incorporation was subsequently amended and restated on April 18, 1996 under the name
IMRÉ Corporation and was subsequently amended on September 16, 1999, March 9, 2001 and amended and
restated on September 22, 2003 (collectively, the Certificate of Incorporation).
Two: The Board of Directors of the Company (the Board), acting in accordance with
the provisions of Sections 141 and 242 of the General Corporation Law of the State of Delaware,
adopted resolutions amending the Companys Certificate of Incorporation as follows:
Section A of Article IV shall be amended and restated to read in its
entirety as follows:
This Corporation is authorized to issue two classes of stock to be
designated, respectively, Common Stock and Preferred Stock. The
total number of shares which the Corporation is authorized to issue
is 105,000,000 shares. 90,000,000 shares shall be Common Stock,
each having a par value of $.001. 15,000,000 shares shall be
Preferred Stock, each having a par value of $.001.
Three: Thereafter pursuant to a resolution of the Board, this Certificate of
Amendment was submitted to the stockholders of the Company for their approval, and was duly adopted
in accordance with the provisions of Section 242 of the General Corporation Law of the State of
Delaware.
In Witness Whereof, the Company has caused this Certificate of Amendment to be signed
by its Executive Vice President, Chief Operating Officer and Chief Financial Officer this 15th day
of June 2009.
Cypress Bioscience, Inc. |
||||
By: | /s/ Sabrina Martucci Johnson | |||
Sabrina Martucci Johnson | ||||
Executive Vice President, Chief Operating Officer and Chief Financial Officer |
||||